B of A Securities Reiterates Buy Rating on Kymera Therapeutics
B of A Securities maintains its buy rating for Kymera Therapeutics with a $125 price target, a 9.01% upside from the current price.
Key Points
- B of A Securities reiterated its buy rating on Kymera Therapeutics, Inc. (KYMR) with a $125 price target on June 30, 2026.
- B of A Securities's $125 price target implies 9.01% upside from Kymera Therapeutics, Inc.'s ($KYMR) current $114.67 share price.
- Shares of KYMR traded near $109.32 on Tuesday, with a market cap of approximately $8.89 billion and a 52-week high of $130.05.
- Recent insider activity includes sales by BVF Partners and purchases by Chief Business Officer Noah Goodman.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B of A Securities reiterated its buy rating on Kymera Therapeutics, Inc. (NasdaqGM: KYMR) on June 30, 2026, setting a price target of $125. This evaluation comes as the company continues to focus on its biopharmaceutical developments.
B of A Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Kymera Therapeutics, Inc. Stock Down 2.9%
Shares of Kymera Therapeutics traded near $109.32 on Tuesday. The company has a market cap of approximately $8.89 billion. Despite reporting negative earnings per share, the stock has shown significant volatility, with a 52-week high of $130.05 and a low of $36.65. The company's forward P/E ratio is not meaningful as it isn't profitable, and the beta is 2.027, indicating higher volatility compared to the market. Kymera's current and quick ratios stand at 10.814 and 10.391 respectively, suggesting strong liquidity.
$KYMR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Kymera Therapeutics reported revenue of $51.48 million, reflecting a growth rate of 55.5%. However, the company is not yet profitable, with a net margin of zero and a return on equity of -27.1%. Its next earnings report is scheduled for August 10, 2026.
Insider Buying and Selling at Kymera Therapeutics, Inc.
Recent insider activity at Kymera Therapeutics included sales by BVF Partners on June 26, 2026, and by Bruce Booth on June 25, 2026, under a planned transaction. Chief Business Officer Noah Goodman executed a mix of sales and purchases on June 25, 2026, with some transactions being planned.
Analysts Set New Price Targets
Alongside B of A Securities, other firms have maintained their buy ratings for Kymera Therapeutics. On June 29, 2026, Truist Securities maintained a buy rating with a $136 price target, while B. Riley Securities set a target of $155. Canaccord Genuity also maintained a buy rating with a $129 target on June 26, 2026. The consensus among analysts is a strong buy, with a mean price target of approximately $123.05 based on 21 analyst opinions.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a biotechnology company based in Watertown, Massachusetts. It focuses on developing small molecule therapeutics that target disease-causing proteins through the body's natural protein degradation processes. The company is working on several clinical-stage programs, including treatments for atopic dermatitis, autoimmune diseases, and various cancers. Founded in 2015, Kymera collaborates with Sanofi for drug development in non-oncology fields.
Bottom Line
B of A Securities' reiteration of a buy rating with a $125 target reflects confidence in Kymera Therapeutics' potential. Investors watch these ratings closely, as they provide insights into the company's prospects. However, it is important to remember that these analyst ratings are based on past data and projections, which may not fully capture future market conditions.
Get Kymera Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KYMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.